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Introduction: It is known that anticitrullinated peptide antibody (ACPA)–positive rheumatoid arthritis (RA) has a
preclinical phase. Whether this phase is also present in ACPA-negative RA is unknown. To determine this, we studied
ACPA-negative arthralgia patients who were considered prone to progress to RA for local subclinical inflammation
observed on hand and foot magnetic resonance imaging (MRI) scans.
Methods: We studied a total of 64 ACPA-negative patients without clinically detectable arthritis and with arthralgia
of the small joints within the previous 1 year. Because of the character of the patients’ symptoms, the rheumatologists
considered these patients to be prone to progress to RA. For comparisons, we evaluated 19 healthy, symptom-free
controls and 20 ACPA-negative RA patients, who were identified according to the 1987 American Rheumatism
Association criteria. All participants underwent MRI of unilateral wrist, metacarpophalangeal and metatarsophalangeal
joints. Synovitis and bone marrow oedema (BME) were scored according to the OMERACT rheumatoid arthritis
magnetic resonance imaging scoring system, and the scores were summed to yield the ‘MRI inflammation score’.
Scores were compared between groups. Among the ACPA-negative arthralgia patients, MRI inflammation scores were
related to C-reactive protein (CRP) levels and the tenderness of scanned joints.
Results: MRI inflammation scores increased progressively among the groups of controls and ACPA-negative arthralgia
and RA patients (median scores = 0, 1 and 10, respectively; P < 0.001). The MRI inflammation scores of ACPA-negative
arthralgia patients were significantly higher than those of controls (P = 0.018). In particular, the synovitis scores were
higher in ACPA-negative arthralgia patients (P = 0.046). Among the ACPA-negative arthralgia patients, inflammation
was observed predominantly in the wrist (53%). The synovitis scores were associated with CRP levels (P = 0.007) and
joint tenderness (P = 0.026). Despite the limited follow-up duration, five patients developed clinically detectable arthritis.
These five patients had higher scores for MRI inflammation (P = 0.001), synovitis (P = 0.002) and BME (P = 0.003)
compared to the other patients.
Conclusion: Subclinical synovitis was observed in the small joints of ACPA-negative arthralgia patients, and especially
in patients whose conditions progressed to clinically detectable arthritis. This finding suggests the presence of a
preclinical phase in ACPA-negative RA. Further longitudinal studies of these lesions and patients are required to
confirm this hypothesis.* Correspondence: H.W.van_Steenbergen@lumc.nl
1Department of Rheumatology, Leiden University Medical Center, P.O. Box
9600, 2300 RC, Leiden, the Netherlands
Full list of author information is available at the end of the article
© 2014 van Steenbergen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
van Steenbergen et al. Arthritis Research & Therapy 2014, 16:R92 Page 2 of 7
http://arthritis-research.com/content/16/2/R92Introduction
Early recognition of rheumatoid arthritis (RA) and early
treatment initiation of it have been proven to be effective
in reducing the disease burden over time [1,2]. For the past
few years, interest in the early disease phase has also co-
vered the preclinical phase of RA [3]. It has been shown
that RA-specific autoantibodies [4,5] and serologic inflam-
matory markers are increased months to years before de-
velopment of RA [6,7]. Also, subclinical inflammation
locally in the small joints of autoantibody-positive arthral-
gia patients without clinical arthritis was visualised using
ultrasonography, positron emission tomography (PET) and
magnetic resonance imaging (MRI) [8-10]. Previous studies
that investigated the preclinical phase of RA mainly or
solely focused on anticitrullinated peptide antibody (ACPA)
positive RA. Consequently, it is not known whether ACPA-
negative RA also has a preclinical phase. Nonetheless, up
to half of all patients in early RA cohorts are ACPA-
negative [1,11,12].
MRI is a suitable modality for studying early inflam-
matory changes in the small joints of patients in the pre-
clinical phase of RA. It detects synovitis and is the only
imaging modality that depicts bone marrow oedema
(BME), an MRI feature that is strongly associated with
disease progression [13-15]. The availability of dedicated
MRI scanners have increased the accessibility and com-
fort of MRI scanning. Additionally, the presence of a va-
lidated scoring methodology (the Outcome Measures in
Rheumatology Clinical Trials (OMERACT) rheumatoid
arthritis magnetic resonance imaging scoring system
(RAMRIS)) allows comparison of the extent and severity
of MRI features for research purposes [15].
In the present study, we used MRI of the hand and foot
to evaluate whether ACPA-negative RA, like ACPA-
positive RA, has a preclinical phase with local inflamma-
tion in small joints. Persons with any type of arthralgia are
prevalent in the general population and at rheumatologic
outpatient clinics. Because the majority of arthralgia pa-
tients are ACPA-negative and will never develop RA, it is
challenging to identify the ACPA-negative arthralgia pa-
tients that might be in a preclinical phase of RA. We stu-
died ACPA-negative patients without clinical arthritis and
with recent-onset arthralgia of small joints who, because
of the character of their symptoms, were considered prone
to have disease likely to progress to RA by the treating
rheumatologists. For comparisons, healthy controls and
ACPA-negative RA patients were also studied.
Methods
Participants
Three groups of participants were studied. The first
group consisted of 64 ACPA-negative arthralgia patients
recruited at the Leiden University Medical Center be-
tween April 2012 and June 2013. The rheumatologistswere requested to include patients who presented to the
outpatient clinic without clinical arthritis upon physical
examination but with arthralgia of the hand or foot joints
of less than 1 year’s duration of a type that was considered
to have an increased chance to progress to RA. This suspi-
cion was based on symptoms and signs, combined with the
gut feelings of the rheumatologists. Hence, based on the
rheumatologists’ clinical impression, these patients were
considered to be in a preclinical phase of RA. The rheuma-
tologists were encouraged to include patients whom they
had otherwise also followed and not discharged because
they were concerned that these patients had an increased
risk for RA development. Because no type of arthralgia has
yet been defined to be specific for the preclinical phase of
RA, we could not assign more specific criteria with regard
to the type of arthralgia patients to be included. Impor-
tantly, when another explanation for the patients’ arthralgia
was more likely, such as fibromyalgia, osteoarthritis or an
inflammatory rheumatic disease, these patients were not
included. In our present study, among all patients with
arthralgia, the 64 patients who tested negative for ACPA
(anticyclic citrullinated peptide 2–negative) (Euro Diagnos-
tica AB, Nijmegen, the Netherlands) were selected. The
second group comprised 20 ACPA-negative patients who
met the 1987 American Rheumatism Association criteria
for RA [16]. These patients were included in the Leiden
Early Arthritis Clinic cohort between August 2010 and
July 2012. The third group consisted of 19 healthy
controls without joint symptoms. Written informed
consent was obtained from all participants. Approval
of the study protocol was obtained from the local
Medical Ethics Committee of the Leiden University
Medical Center.
Magnetic resonance imaging
All participants underwent MRI of the wrist, metacarpo-
phalangeal (MCP) joints and metatarsophalangeal (MTP)
joints with an ONI MSK Extreme 1.5 T MRI scanner (GE
Healthcare Life Sciences, Madison, WI, USA). In the arth-
ralgia and RA patients, MRI of the most painful side was
performed within 2 weeks after the first visit. In cases of
equally severe symptoms on both sides, the dominant side
was scanned. Patients were asked not to use any nonste-
roidal anti-inflammatory drugs (NSAIDs) during the
24 hours before undergoing MRI. The healthy symptom-
free controls underwent MRI of the dominant side. The
following sequences were acquired for MCP joints and
wrists: a coronal T1-weighted fast spin echo (FSE) sequence,
a coronal T2-weighted FSE sequence with fat saturation
and, after intravenous gadolinium contrast enhancement
(0.1 mmol/kg), coronal and axial T1-weighted FSE se-
quences with fat saturation. Axial T1-weighted FSE se-
quences and T2-weighted FSE sequences with fat saturation
of MTP joints were acquired. Owing to time constraints,
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MTP joints. For ethical reasons, contrast agents were not
administered in controls. Synovitis and BME were scored
quantitatively according to the OMERACT RAMRIS system
[15]. The sum of the synovitis and BME scores yielded the
‘MRI inflammation score’. Scoring was performed by one
trained reader, 47% of the scans were read twice and the
within-reader intraclass correlation coefficient for the MRI
inflammation score was 0.91.
Analyses
Comparisons were made using a Mann-Whitney U test,
Kruskal-Wallis test or χ2 test as appropriate. In the ACPA-
negative arthralgia patients, linear regression analyses were
used to study whether C-reactive protein (CRP) level was
associated with MRI-determined inflammation scores. The
associations between tenderness and degree of inflamma-
tion observed on MRI scans were tested by performing
generalized estimating equations. This model took into ac-
count that, in every patient, ten joints were assessed. The
unstructured correlation matrix was used. SPSS version
20.0 software (SPSS, Chicago, IL, USA) was used for calcu-
lations. P-values <0.05 were considered significant.Results
ACPA-negative arthralgia patients prioritized by the
rheumatologists
The rheumatologists were requested to state the primary
reasons why they assumed that the arthralgia patients
had an increased risk for RA development. The main
reasons provided were joint pain that was worst in the
early morning and improved with movement during the
day (thus making it an inflammatory type of arthralgia),
the presence of morning stiffness of ≥60 minutes and/or
a positive family history of RA. The baseline characteris-
tics of the ACPA-negative arthralgia patients, as well as
those of the ACPA-negative RA patients and symptom-
free controls, are presented in Table 1. The ACPA-negative
arthralgia patients who were considered at risk for progres-
sion to RA had a mean age of 42 years, and 72% were fe-
male. The symptoms of most patients had started gradually
(75%) and initially involved the upper extremities (73%).
Tender joints were localized predominantly in the prox-
imal interphalangeal (PIP) joints (60%) and the MCP
joints (52%). Nine patients (14%) were rheumatoid
factor (RF)-positive.
Magnetic resonance imaging findings in the three groups
The median (interquartile range (IQR)) MRI inflamma-
tion scores in symptom-free controls, ACPA-negative
arthralgia patients and ACPA-negative RA patients
were 0 (0 to 1), 1 (1 to 3) and 10 (10 to 16), respectively
(P < 0.001) (Figure 1).Magnetic resonance imaging findings in ACPA-negative
arthralgia patients and symptom-free controls
The ACPA-negative arthralgia patients were compared
with the symptom-free controls (Figure 1). Eight (42.1%)
of the nineteen symptom-free controls and forty-four
(68.8%) of the sixty-four ACPA-negative arthralgia patients
had any sign of inflammation based on MRI (inflamma-
tion score ≥1) (P = 0.035). The median MRI inflammation
scores were significantly higher in the ACPA-negative
arthralgia patients than in controls (P = 0.018). Subse-
quently, synovitis and BME scores were evaluated separ-
ately. This analysis showed that synovitis scores were
significantly higher in ACPA-negative arthralgia patients
than in controls (P = 0.046), in contrast to BME patients
(P = 0.20) (Figure 1). Thus, compared to controls, patients
with ACPA-negative arthralgia in particular had higher
subclinical synovitis scores of small joints.
The proportion of patients with any sign of inflammation
(synovitis and/or BME) on MRI in the wrist, MCP joints
and MTP joints were, respectively, 53.1%, 20.3% and
31.3%. Synovitis was observed predominantly in the inter-
carpal (29.7%), radiocarpal (21.9%), MTP1 (17.2%) and
MCP3 joints (14.1%). BME was most often present in the
capitate (20.3%), lunate (15.6%) and MTP1 joints (15.6%).
Figure 2 shows examples of inflammation visualised on
MRI scans.
Evaluation of rheumatoid factor in ACPA-negative patients
Subsequently, the ACPA-negative arthralgia patients were
assigned to RF-positive (n = 9) and RF-negative (n = 55)
groups. No differences in MRI inflammation, synovitis and
BME scores were observed (P = 0.63, 0.62 and 0.90, re-
spectively) (Additional file 1: Figure S1). We observed
similar differences when the ACPA-negative RA patients
were stratified.
Evaluation of traditional measures of inflammation in
ACPA-negative arthralgia patients
Furthermore, we evaluated whether the degree of inflam-
mation visualised on MRI scans of ACPA-negative arthral-
gia patients was associated with the level of serological
inflammation as measured by CRP levels. The synovitis
score was significantly associated with CRP level (β = 0.10,
P = 0.007), indicating that each 1 mg/L increase in CRP
level resulted in a 0.10 increase in synovitis score. The
BME score was not associated with CRP level (P = 0.88).
Also, the MRI-based inflammation score was not signifi-
cantly associated with CRP level (β = 0.10, P = 0.066).
Subsequently, we studied whether tender joints had
higher MRI-based scores than nontender joints. The pres-
ence of joint tenderness was significantly associated with
synovitis score (P = 0.026, OR = 1.15), indicating that ten-
der joints had 15% higher odds on one-point increase in
synovitis score compared to nontender joints. No
Table 1 Patient characteristicsa
Characteristics Symptom-free controls ACPA-negative arthralgia ACPA-negative RA
(n = 19) (n = 64) (n = 20)
Mean age, yr (SD) 46.2 (11.8) 41.9 (14.3) 58.7 (14.5)
Females, n (%) 15 (78.9) 46 (71.9) 11 (55.0)
Positive family history of RA, n (%) N/A 25 (39.1) 4 (20.0)
Median symptom duration at time of inclusion, wk (IQR) N/A 13.4 (8.4 to 26.4) 17.6 (11.5 to 25.9)
Gradual symptom onset, n (%) N/A 48 (75.0) 12 (60.0)
Initial symptom localization, n (%) N/A
Upper extremities, n (%) 47 (73.4) 10 (50.0)
Lower extremities, n (%) 2 (3.1) 4 (20.0)
Upper and lower extremities, n (%) 15 (23.4) 6 (30.0)
Symmetrical localization, n (%) N/A 46 (71.9) 13 (65.0)
Median morning stiffness, min (IQR) N/A 45 (15 to 90) 120 (30 to 120)
Median tender joint count in 68 joints (IQR) 0 5.5 (3 to 10.8) 12 (4.8 to 17.8)
Median swollen joint count 66 joints (IQR) 0 0 6 (4 to 11)
ACPA positivity (>7.0 IU/ml), n (%) N/A 0 0
IgM RF positivity (>3.5 IU/ml), n (%) N/A 9 (14.1) 3 (15.0)
Increased CRP level (>10 mg/L), n (%) N/A 10 (15.6) 11 (55.0)
aACPA, Anticitrullinated peptide antibody; CRP, C-reactive protein; IQR, Interquartile range; IgM RF, Immunoglobulin M rheumatoid factor; N/A, Not applicable; RA,
Rheumatoid arthritis; SD, Standard deviation.
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derness and BME scores (P = 0.18) or MRI-based inflam-
mation scores (P = 0.53).
Follow-up of ACPA-negative arthralgia patients
The follow-up duration of the ACPA-negative arthralgia
patients was still limited at a median of 9 months (IQR = 5
to 11). During this period, five of the ACPA-negative arth-
ralgia patients developed clinical arthritis as detected by
their rheumatologists during physical examinations (7.8%).
Median (IQR) scores for MRI-based inflammation, syno-
vitis and BME for these patients were, respectively, 5 (4
to 8.5), 3 (1.5 to 7) and 2 (1.5 to 2.5) (Figure 1). These
scores were significantly higher than those of the ACPA-
negative arthralgia patients who did not or had not yet
developed clinical arthritis (inflammation: P = 0.001; syno-
vitis: P = 0.002; and BME: P = 0.003). Of the five patients
who developed clinical arthritis, three were diagnosed with
RA, one with unclassified arthritis and one with psoriatic
arthritis. At the time of clinical arthritis development, all
patients were still ACPA-negative.
Discussion
Early intervention in RA is associated with a more
favourable disease course [1,2]. The recognition that sys-
temic inflammatory markers are increased in the preclin-
ical phase [6,7] and that inflammation is also locally
present in small joints has increased interest in investiga-
tion of the preclinical phase of RA [8-10]. The ultimatehope is that intervention in the preclinical phase will pre-
vent the development of the classical picture of RA. The
large majority of studies on the preclinical phase have fo-
cused on patients with ACPA [3]. To the best of our
knowledge, this study is the first to assess whether local
subclinical inflammation is also present in ACPA-negative
pre-RA patients. We observed that ACPA-negative arth-
ralgia patients had higher MRI-based inflammation scores
than healthy participants and that higher MRI-based syno-
vitis scores were associated with higher CRP levels.
Identifying ACPA-negative arthralgia patients with an
increased chance of developing RA is more challenging
compared to other pre-RA studies were the presence of
RA-related autoantibodies was measured and considered
as a marker of increased risk. In the present study, rheu-
matologists were asked to select patients who, in their
view, had an increased chance of developing RA. Be-
cause no type of arthralgia has yet been defined to be
specific for pre-RA, we could not assign more specific
criteria with regard to the type of arthralgia to be in-
cluded. Retrospectively, the reasons for rheumatologists
to consider patients as having an increased chance for
developing RA were mainly joint pain that was worst in
the early morning and improved with movement during
the day (an inflammatory type of pain), the presence of
morning stiffness of ≥60 minutes and a positive family
history for RA. An advantage of the approach used in
present study is that it resembles current clinical practice.
It is of note that the studied arthralgia patients were
Figure 1 Magnetic resonance imaging-based inflammation scores shown separately for the three study groups. (A) Magnetic
resonance imaging (MRI) inflammation scores (synovitis plus bone marrow edema (BME)). (B) Synovitis scores. (C) Bone marrow oedema
scores. The three study groups are the symptom-free controls, the anticitrullinated peptide antibody (ACPA)–negative arthralgia patients
and the ACPA-negative rheumatoid arthritis (RA) patients, based on the 1987 criteria for RA [16]. The scores presented are for all participants
individually (dots) and the median scores per group (horizontal lines). The red dots indicate the ACPA-negative patients who developed
clinically detectable arthritis during the median follow-up of 9 months. The y-axes are split because RA patients had higher scores than
the symptom-free controls and ACPA-negative arthralgia patients. The presented P-values were obtained by comparing the scores of
ACPA-negative arthralgia patients and symptom-free controls. All P < 0.001 for differences in MRI-based inflammation, synovitis and BME
scores between the three groups.
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who visited our outpatient clinic between April 2012 and
June 2013. The observation that 69% of the patients who
were considered to have an increased chance of developing
RA had any signs of subclinical inflammation on MRI
scans might indicate that the rheumatologists did reason-
ably well in selecting ACPA-negative arthralgia patients.
The MRI inflammation scores were higher in ACPA-
negative arthralgia patients than in symptom-free controls.
Patients with ACPA-negative RA had much higher MRI-
based inflammation scores than those in the other two
groups, which was expected because these patients had
clinically detectable joint inflammation. The inflammatory
lesions observed in ACPA-negative arthralgia patients were
small, but were located at locations that are known to be
affected in RA, such as the intercarpal bones and the
MCP3 and MTP1 joints [14].
Interestingly, MRI-based synovitis scores, but not BME
scores, were increased in ACPA-negative arthralgia pa-
tients compared to symptom-free controls. BME is more
prevalent in ACPA-positive RA patients than in ACPA-
negative RA patients, and it is a strong predictor ofprogression of joint destruction [13,14,17]. The finding of
no increase in BME score in the preclinical phase of
ACPA-negative patients might suggest that BME is not
an early phenomenon in ACPA-negative RA or reflects
a lower prevalence of BME in ACPA-negative RA pa-
tients, a subset of RA that is also characterized by less
severe radiological progression [18]. Larger and longitu-
dinal studies are required to determine the value of
BME in this disease subset.
This study has several limitations. The number of
symptom-free controls studied is relatively low. Second, for
ethical reasons, the controls did not receive intravenous
contrast fluid. Researchers in previous studies have sug-
gested that eliminating contrast enhancement does not
affect BME scores, although it may affect the reliability of
synovitis scoring [19,20]. In studies in which MRI scans
with contrast enhancement were used as the gold standard,
the sensitivity for synovitis scoring on the basis of high-
field MRI without contrast enhancement has been re-
ported to be high (78% to 90%), but the specificity has been
reported to be moderate (31% to 79%) [19,20]. As a conse-
quence of the moderate specificity in this study, the scores
Figure 2 Subclinical inflammation visualised by magnetic resonance imaging of two different anticitrullinated peptide antibody–negative
arthralgia patients without clinically detectable arthritis. Images show the metacarpophalangeal (MCP) joints and wrists of anticitrullinated
peptide antibody (ACPA)–negative arthralgia patients without clinically detectable arthritis. The white lines in the top coronal images reflect the
localisation of the bottom axial images. (A) Post–contrast enhancement coronal (A1) and axial (A2) T1-weighted fast spin echo (FSE) images with fat
saturation showing enhancement of the MCP2, MCP3 and MCP5 joints, which is consistent with active synovitis. Also, pronounced tenosynovitis in the
third flexor tendon is present, although tenosynovitis is not included in the OMERACT rheumatoid arthritis magnetic resonance imaging scoring system
score and was not evaluated in the present study. This patient developed clinically detectable arthritis during follow-up. (B) Post–contrast enhancement
coronal (B1) and axial (B2) T1-weighted FSE images with fat saturation showing bone marrow oedema (BME) and erosions (confirmed on the
pre–contrast enhancement T1-weighted FSE sequence) in the lunate. Also, there is active synovitis in the intercarpal joint.
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mated. Consequently, the differences in synovitis scores
between the arthralgia patients and the healthy controls
might have been underestimated. So, although the absence
of contrast enhancement in the controls is a clear limita-
tion, the results of previous studies [19,20] indicate that
the differences might have been larger in cases of contrast
administration to controls. Another limitation is the short
duration of follow-up, which ranged from 1 to 16 months.
The present study therefore provides mainly cross-sectional
data. Longer follow-up is required to determine which
ACPA-negative arthralgia patients and which inflammatory
lesions detected by MRI are most predictive of progression
to clinically detectable arthritis. Nonetheless, it is notable
that arthralgia patients who developed clinical arthritis had
higher MRI-based inflammation scores. A research ques-
tion that remains unanswered is the long-term course of in-
flammation detected on MRI scans. Serial MRI scans are
needed to determine whether MRI-based inflammation is
relapsing, remitting or stable over time.
Conclusions
ACPA-negative arthralgia patients, especially patients
whose conditions progress to clinical arthritis, have sub-
clinical inflammation visualised on MRI scans of the handand foot, suggesting that also ACPA-negative RA has a
preclinical symptomatic phase.Additional file
Additional file 1: Figure S1. Magnetic resonance imaging–based
inflammation scores. (A) Scores for synovitis plus bone marrow edema.
(B) Scores for synovitis. (C) Scores for bone marrow edema (BME). Scores are
given separately for the anticitrullinated peptide antibody (ACPA)–negative
patients with or without rheumatoid factor (RF). The scores of all participants
are presented individually (dots) and as the median scores per group
(horizontal line). The y-axes are split because the RA patients had higher
scores than the ACPA-negative arthralgia patients. The presented P-values
were obtained by comparing the scores of the RF-negative and RF-positive
patients within the group of ACPA-negative arthralgia and ACPA-negative
RA patients.Abbreviations
ACPA: Anticitrullinated peptide antibody; BME: Bone marrow oedema;
CRP: C-reactive protein; FSE: Fast spin echo; IQR: Interquartile range;
MCP: Metacarpophalangeal; MRI: Magnetic resonance imaging;
MTP: Metatarsophalangeal; NSAID: Nonsteroidal anti-inflammatory drug;
OMERACT: Outcome Measures in Rheumatology; PET: Positron emission
tomography; PIP: Proximal interphalangeal; RA: Rheumatoid arthritis;
RAMRIS: OMERACT rheumatoid arthritis magnetic resonance imaging scoring
system; RF: Rheumatoid factor.
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